Detailed explanation of ibrutinib/ibrutinib 2024 medical insurance pricing and reimbursement

As 2024 approaches, the medical insurance price and reimbursement policy of Ibrutinib, a star drug for the treatment of blood cancer, in the domestic market has attracted much attention. This original drug is widely available in capsule form and has been successfully included in the Class B medical insurance directory, providing financial support to patients who meet specific indications. At present, the common specification is 140mg*90 ibrutinib capsules, with a market price of about 10,000 yuan. However, due to differences in reimbursement rates from local medical insurance, the actual fees paid by patients may vary. In order to obtain the most accurate reimbursement information, patients are advised to consult their local medical insurance bureau or hospital.

In China, patients eligible for medical insurance reimbursement mainly include patients with mantle cell lymphoma(MCL) who have received at least one treatment in the past, patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and patients with Waldenström's macroglobulinemia (WM). When these patients use ibrutinib, they must strictly follow the doctor's instructions and instructions for use and dosage.

Ibrutinib is a small molecule drug whose mechanism of action is to inhibit the proliferation and survival of B cells by irreversibly binding to Bruton's tyrosine kinase (BTK). This combination blocks a B-cell receptor pathway that is abnormally active in B-cell cancers, making ibrutinib an effective drug for treating this type of cancer. In addition, ibrutinib can also bind to C-terminal Src kinase and inhibit the kinase activity of these non-target receptors, further affecting cell differentiation and growth. However, during the treatment of chronic lymphocytic leukemia, patients may experience some side effects, such as left atrial enlargement and atrial fibrillation, so close monitoring and adjustment of the treatment plan are required.